These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 25495067)

  • 1. Clinical predictors and time course of the improvement in β-cell function with short-term intensive insulin therapy in patients with Type 2 diabetes.
    Stein CM; Kramer CK; Zinman B; Choi H; Opsteen C; Retnakaran R
    Diabet Med; 2015 May; 32(5):645-52. PubMed ID: 25495067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
    Lo C; Jun M; Badve SV; Pilmore H; White SL; Hawley C; Cass A; Perkovic V; Zoungas S
    Cochrane Database Syst Rev; 2017 Feb; 2(2):CD009966. PubMed ID: 28238223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
    Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The response to short-term intensive insulin therapy in type 2 diabetes.
    Retnakaran R; Yakubovich N; Qi Y; Opsteen C; Zinman B
    Diabetes Obes Metab; 2010 Jan; 12(1):65-71. PubMed ID: 19740080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
    Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-term intensive insulin therapy could be the preferred option for new onset Type 2 diabetes mellitus patients with HbA1c > 9.
    Weng J
    J Diabetes; 2017 Oct; 9(10):890-893. PubMed ID: 28661564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baseline HbA1c predicts attainment of 7.0% HbA1c target with structured titration of insulin glargine in type 2 diabetes: a patient-level analysis of 12 studies.
    Riddle MC; Vlajnic A; Zhou R; Rosenstock J
    Diabetes Obes Metab; 2013 Sep; 15(9):819-25. PubMed ID: 23489438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Asian patients with type 2 diabetes inadequately controlled on basal or pre-/self-mixed insulin: a 26-week, randomised, treat-to-target trial.
    Kaneko S; Chow F; Choi DS; Taneda S; Hirao K; Park Y; Andersen TH; Gall MA; Christiansen JS;
    Diabetes Res Clin Pract; 2015 Jan; 107(1):139-47. PubMed ID: 25498130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naïve patients with type 2 diabetes receiving oral antidiabetes agents.
    Jacober SJ; Scism-Bacon JL; Zagar AJ
    Diabetes Obes Metab; 2006 Jul; 8(4):448-55. PubMed ID: 16776752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intensifying insulin regimen after basal insulin optimization in adults with type 2 diabetes: a 24-week, randomized, open-label trial comparing insulin glargine plus insulin glulisine with biphasic insulin aspart (LanScape).
    Vora J; Cohen N; Evans M; Hockey A; Speight J; Whately-Smith C
    Diabetes Obes Metab; 2015 Dec; 17(12):1133-41. PubMed ID: 26085028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial.
    Weng J; Li Y; Xu W; Shi L; Zhang Q; Zhu D; Hu Y; Zhou Z; Yan X; Tian H; Ran X; Luo Z; Xian J; Yan L; Li F; Zeng L; Chen Y; Yang L; Yan S; Liu J; Li M; Fu Z; Cheng H
    Lancet; 2008 May; 371(9626):1753-60. PubMed ID: 18502299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of response to early basal insulin treatment in patients with type 2 diabetes--the EARLY experience.
    Hanefeld M; Fleischmann H; Schiffhorst G; Bramlage P
    Diabetes Technol Ther; 2014 Apr; 16(4):241-6. PubMed ID: 24229089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of a basal insulin + 2-3 oral antihyperglycaemic drugs regimen versus a twice-daily premixed insulin + metformin regimen after short-term intensive insulin therapy in individuals with type 2 diabetes: The multicentre, open-label, randomized controlled BEYOND-V trial.
    Pan Q; Li Y; Wan H; Wang J; Xu B; Wang G; Jiang C; Liang L; Feng W; Liu J; Wang T; Zhang X; Cui N; Mu Y; Guo L;
    Diabetes Obes Metab; 2022 Oct; 24(10):1957-1966. PubMed ID: 35642463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Commencing insulin glargine 100 U/mL therapy in individuals with type 2 diabetes: Determinants of achievement of HbA1c goal less than 7.0.
    Owens DR; Landgraf W; Frier BM; Zhang M; Home PD; Meneghini L; Bolli GB
    Diabetes Obes Metab; 2019 Feb; 21(2):321-329. PubMed ID: 30520217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors for successful insulin therapy in subjects with type 2 diabetes.
    Wolffenbuttel BH; Sels JP; Rondas-Colbers GJ; Menheere PP
    Neth J Med; 1999 Feb; 54(2):63-9. PubMed ID: 10079680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Dapagliflozin on Glycemic Variability in Patients with Type 2 Diabetes under Insulin Glargine Combined with Other Oral Hypoglycemic Drugs.
    Luo M; Kong X; Wang H; Zhai X; Cai T; Ding B; Hu Y; Jing T; Su X; Li H; Ma J
    J Diabetes Res; 2020; 2020():6666403. PubMed ID: 33299890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
    Hollander P; Cooper J; Bregnhøj J; Pedersen CB
    Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.
    Heller S; Koenen C; Bode B
    Clin Ther; 2009 Oct; 31(10):2086-97. PubMed ID: 19922879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Twice-daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin-naïve adults with Type 2 diabetes.
    Franek E; Haluzík M; Canecki Varžić S; Sargin M; Macura S; Zacho J; Christiansen JS
    Diabet Med; 2016 Apr; 33(4):497-505. PubMed ID: 26435365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determinants of reversibility of β-cell dysfunction in response to short-term intensive insulin therapy in patients with early type 2 diabetes.
    Kramer CK; Choi H; Zinman B; Retnakaran R
    Am J Physiol Endocrinol Metab; 2013 Dec; 305(11):E1398-407. PubMed ID: 24129396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.